Desvenlafaxine Monotherapy in Dysthymia

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Dysthymic Disorder
Interventions
DRUG

Desvenlafaxine

Patients will be initiated on 50 mg/day of Desvenlafaxine. No dose changes will be allowed for the first four weeks. If there is partial or no response after four weeks, dosage will then be increased to 100mg/day, based on tolerability and the Investigator's judgment.

Trial Locations (2)

L5M 4N4

Medical Research Associates, Mississauga

M5T 1R8

Centre for Addiction and Mental Health, Toronto

All Listed Sponsors
lead

Centre for Addiction and Mental Health

OTHER

NCT01948895 - Desvenlafaxine Monotherapy in Dysthymia | Biotech Hunter | Biotech Hunter